Sanofi, Sarclisa and multiple myeloma
EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma
EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H
Sanofi: Sarclisa Recommended for EU Approval by CHMP to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...
Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination ...
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...
Sanofi will keep a significant stake in the ... Another great milestone is the approval with Sarclisa in the US for adult patients with newly diagnosed multiple myeloma ineligible for ...
Sanofi SNY reported third-quarter 2024 adjusted ... over year to €92 million due to generic competition. In Oncology, Sarclisa sales rose 23.7% year over year to €114 million, driven by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback